Care Team Strategies in IBD: Best Practices for Shared Decision Making & Treatment Selection in the Era of Predictive Medicine

Program Overview

To educate clinicians on how to maximize use of the Inflammatory Bowel Disease Clinical Decision Support Tool (IBD CDST) when used to assess disease complication risk, personalize treatment selection, improve shared decision making, and facilitate collaborative care.

0.5 CE Credit(s)

Expires: July 14, 2025

Target Audience

Gastroenterology and primary care clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

Assess risk for disease complications in patients with inflammatory bowel disease (IBD)
Utilize the IBD CDST to recommend targeted therapies for patients with IBD
Integrate the unique roles of the interprofessional care team when engaging in CDST-backed shared decision making for optimal management of IBD

Activity Faculty

Emily M. Block, APRN, FNP-C

Nurse Practitioner
Northwestern Medical Group
Chicago, Illinois

Aaron Cohn, MD

Gastroenterologist
Northwestern Medicine
Lake Forest, Illinois

Parambir Dulai, MD

Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology and Hepatology
Feinberg School of Medicine Northwestern University
Chicago, llinois

Supporter Statement

This activity is supported by an independent medical education grant from Takeda Pharmaceuticals U.S.A., Inc.

Provider Statement

Provided by RMEI Medical Education, LLC.

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Emily M. Block, APRN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

Aaron Cohn, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Parambir Dulai, MD, has relevant financial relationship(s) with AbbVie, Abivax, Adiso, Bristol-Myers Squibb, Geneoscopy, Janssen, Lilly, Pfizer, Roivant, Takeda (Consultant).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA-4008290-0000-24-006-H01-P)
Type of Activity: Knowledge

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation and Request for Credit

To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].

Users must:

Read the learning objectives and faculty disclosures
Participate in the activity
Complete the activity evaluation

There is no fee to participate.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 